Enterpreneurs and business people conference in modern meeting room

Aerie Pharmaceuticals, Inc. [NASDAQ:AERI]: Analyst Rating and Earnings

Expert stock traders often make certain they pay attention what leading Wall Street analysts think regarding a potential stock purchase. As it relates to Aerie Pharmaceuticals, Inc. [AERI] currently, the latest ratings from Wall St. experts that can be seen publicly is related to the fiscal quarter that’s scheduled to end in December. On average, stock market experts give AERI an Outperform rating. Its stock price has been found in the range of 109.35 to 257.46. This is compared to its latest closing price of $40.30.

Wall Street analysts provide their ratings on a scale of 1 to 5, and the current average score for Aerie Pharmaceuticals, Inc. [AERI] is sitting at 1.73. This is compared to 1 month ago, when its average rating was 1.73.

For the quarter ending in Sep-18 Aerie Pharmaceuticals, Inc. [AERI] generated $0.01 billion in sales. That’s 24.19% higher than the average estimate of $0.01 billion as provided by Wall Street analysts. The three indicators above suggest that overall, this stock is demonstrating a mixed bag of positive appeal and some drawbacks, making it a somewhat risky investment that also has the potential to generate high ROI in the long run.

Pay attention to the next-scheduled financial results for this company to be released, which is slated for Wed 27 Feb (In 15 Days).

Fundamental Analysis of Aerie Pharmaceuticals, Inc. [AERI]

Turning to investigate this organization’s capital structure, Aerie Pharmaceuticals, Inc. [AERI] has generated a Total Debt to Total Equity ratio of 91.33. Similarly, its Total Debt to Total Capital is 47.73, while its Total Debt to Total Assets stands at 42.66. Looking toward the future, this publicly-traded company’s Long-Term Debt to Equity is 91.33, and its Long-Term Debt to Total Capital is 47.73. This company has a healthy balance between its debt and its current holdings, suggesting it is a reliable investment due to its ability to leverage debt in an efficient way.

What about valuation? This company’s Enterprise Value to EBITDA is -11.85. The Enterprise Value to Sales for this firm is now 175.84, and its Total Debt to Enterprise Value stands at 0.06. Aerie Pharmaceuticals, Inc. [AERI] has a Price to Book Ratio of 16.28.

This publicly-traded organization’s liquidity data is also interesting: its Quick Ratio is 10.09 and its Current Ratio is 10.09. This company, considering these metrics, has a healthy ratio between its short-term liquid assets and its short-term liabilities, making it a less risky investment.

Performance Indicators

Let’s now turn our attention to trading performance: Aerie Pharmaceuticals, Inc. [AERI] has 48.47M shares outstanding, amounting to a total market cap of $1.95B. Its stock price has been found in the range of 32.18 to 74.75. At its current price, it has moved by -43.69% from its 52-week high, and it has moved 30.80% from its 52-week low.

This stock’s Beta value is currently 1.01, which indicates that it is more volatile that the wider market. This stock’s Relative Strength Index (RSI) is at 45.31. This RSI score is good, suggesting this stock is neither overbought or oversold.

Conclusion: Is Aerie Pharmaceuticals, Inc. [AERI] a Reliable Buy?

Shares of Aerie Pharmaceuticals, Inc. [AERI], on the whole, present investors with both positive and negative signals. Wall Street analysts have mixed reviews when it comes to the 12-month price outlook, and this company’s financials show a combination of strengths and weaknesses. Based on the price performance, this investment is somewhat risky while presenting reasonable potential for ROI.